Biopharma PEG Scientific Inc.

Supplier of high purity PEG derivatives and linkers, monodisperse PEG, ADC PEG linkers, PROTAC linkers, PEGylation services, etc.

[Biopharma PEG Scientific Inc. @biochempeg]

🔬 Monodispersed PEG linkers for precise bioconjugation

✔ Defined MW & structure
✔ Strong solubility & low immunogenicity
✔ Flexible groups: Azide, Amine, NHS, Maleimide, BOC/FMOC, etc

g–kg scale | GMP available https://t.co/C4KDDpvFh5
#PEG #ADC #Bioconjugation

[Biopharma PEG Scientific Inc. @biochempeg]

The ADC breakout was just the beginning. 🚀

With Enhertu nearing $5B in sales, the industry is officially pivoting to the XDC (Everything-Drug Conjugate) era.

From PDCs to RDCs and AOCs, the "modular" drug revolution is here. 🧬
https://t.co/inFREQMzHN

[Biopharma PEG Scientific Inc. @biochempeg]

🌸 Multi-Arm PEG for PEGylation

Why Multi-arm PEG
✔ Larger hydrodynamic size
✔ Improved steric shielding
✔ Longer circulation time

Multiarm PEGs are explored in PEGylated therapeutics like IZERVAY, Skytrofa, YORVIPATH,etc

Explore our Multi-Arm PEG: https://t.co/MxHGiIhJqg

[Biopharma PEG Scientific Inc. @biochempeg]

Happy New Year! Thank you to all our clients and partners for a great year. Wishing you success and growth in the year ahead.
#happynewyear #NewYear2026

[Biopharma PEG Scientific Inc. @biochempeg]

🦃 This Thanksgiving, we just want to say thank you to everyone who’s been working with us this year.

To keep your projects moving:
• >95% purity, low impurities
• From gram to kg, at a fair price

🔗 https://t.co/lQv623CZkC
📩 [email protected]
#Thanksgiving #PEG #ADC

[Biopharma PEG Scientific Inc. @biochempeg]

📊 ADC Market Update H1 2025
Global sales hit ~$8B (FY 2025 est. >$16B)
Top sellers: Enhertu, Padcev, Kadcyla, Polivy, Adcetris, Trodelvy
41 ADCs in Phase III across 50+ targets 🚀
Rising stars: HER3, B7-H3, CLDN18.2, ROR1
👉 Full article: https://t.co/BMmrsSpudS

#ADC #Oncology

[NEJM @NEJM]

BETAMI–DANBLOCK trial: Beta-blockers are recommended for myocardial infarction and reduced left ventricular ejection fraction, but potential benefits for preserved or mildly reduced ejection fraction are unclear. Research findings are summarized in a new Quick Take video. https://t.co/W9c5ZsKF6l

[Biopharma PEG Scientific Inc. @biochempeg]

3 of 19 approved ADCs use PEG linkers for stability & precision:
🔹 Trodelvy®
🔹 Zynlonta®
🔹 Jiataile® (China)
Biopharma PEG delivers >95% purity PEG linkers (impurities <0.5%) to power ADC innovation.
https://t.co/NkNFytlHJs

[Scott Isaacs @scottisaacsmd]

Breaking! The FDA has approved Wegovy #semaglutide to treat #MASH in adults with moderate-to-advanced fibrosis.
https://t.co/NY62l47vo4

[Biopharma PEG Scientific Inc. @biochempeg]

🚀 PROTACs are moving fast: 40+ candidates in trials, targeting AR, ER, BTK & more.
3 in Phase 3:
🔹 ARV-471 (FDA NDA, PDUFA June 2026)
🔹 BMS-986365
🔹 BGB-16673
https://t.co/St2vNBolUP
A new drug class may be just around the corner. 👀
#PROTAC #Oncology #DrugDiscovery

[Biopharma PEG Scientific Inc. @biochempeg]

🔹 Y-shape-PEG-NHS (2-Arm PEG-NHS) enables efficient amine-reactive conjugation for proteins, peptides & hydrogels.

💡 Ideal for tissue engineering & controlled drug release.

👉 From lab to commercial scale: [email protected]

#PEGylation #Biotech #DrugDelivery #Hydrogels

[Biopharma PEG Scientific Inc. @biochempeg]

Just revealed at #ACS2025: BMS-986238, a macrocyclic PD-L1 inhibitor with a PEG linker + C18 fatty acid for long half-life & oral potential.

Biopharma PEG supports such advances with custom PEGs for next-gen therapeutics.
🔗 https://t.co/apKqBiGQMI

#PEGylation #BMS986238

[Biopharma PEG Scientific Inc. @biochempeg]

Featured PEGs from Biopharma PEG!
✅ Monodispersed & Polydispersed
✅ GMP Grade
✅ From grams to 100 kg
🔗 https://t.co/z8VQEVQUoA
📩 [email protected]
#PEGs #Biopharma #ADC #GMP

[Biopharma PEG Scientific Inc. @biochempeg]

HER3-DXd BLA withdrawn.

But at #ASCO25:
✅ Zenocutuzumab FDA-approved
✅ BL-B01D1: ORR 69.2% (EGFR ex20ins NSCLC)
✅ DB-1310: Solid early results
HER3 isn't done—bispecifics and combos may lead the way.
#NSCLC #HER3 #ADC #Oncology https://t.co/7ujvkzQqf9

[Biopharma PEG Scientific Inc. @biochempeg]

🚨 Big News!
Biopharma PEG’s HZ-PEG-HZ (1K) has received FDA Type II DMF approval (No. 041864) ✅
🔬 GMP-grade
📦 Supply: mg to 100 kg
💊 Ready to support global drug development!
https://t.co/OkDTJQL6VI
📩 [email protected]
#FDA #DMF #PEGylation #DrugDelivery #BiopharmaPEG

[Biopharma PEG Scientific Inc. @biochempeg]

🚨 PROTAC 2025 Update!
Top degraders enter Phase 3:
🔹 ARV-471 (ER+)
🔹 BMS-986365 (AR)
🔹 BGB-16673 (BTK)
Targeting tough diseases with next-gen protein degradation tech.
Full story 👉 https://t.co/St2vNBolUP

#PROTAC #Oncology #Biotech #ARV471 #BMS986365 #BGB16673

[Biopharma PEG Scientific Inc. @biochempeg]

🚀 Dual-payload ADCs = the next big leap in cancer therapy!
🎯 Two payloads, one antibody = more power, less resistance.
🔥 KH815 becomes the first to enter clinical trials.
https://t.co/DE6zaK0OMa
#ADC #CancerResearch #Oncology #Biotech #KH815 #DualPayloadADC #AACR2025

[Biopharma PEG Scientific Inc. @biochempeg]

🚀 PEGylated lipids boost stability & circulation in mRNA vaccines, siRNA, & anti-cancer drugs! Their structure affects immune response & drug efficacy—a game-changer in #DrugDelivery.

💡 Discover Biopharma PEG’s high-quality PEG lipids today!
🔗 https://t.co/kPKr3fxjcV
#LNP

[Biopharma PEG Scientific Inc. @biochempeg]

🚀 The #ADC market has surpassed $10B in sales! In 2024:
💥 Enhertu: $3.75B
💥 Kadcyla: $2.32B
💥 Padcev: $1.59B
💥 Adcetris: $1.91B
💥 Trodelvy: $1.31B (+24% from 2023)
17 ADC drugs are now approved worldwide! 🌍
🔗 Learn More: https://t.co/3TAHvwL2pp
#Biotech #CancerTherapy

[Biopharma PEG Scientific Inc. @biochempeg]

🚨 FDA APPROVES Datroway (datopotamab deruxtecan) for HR-positive, HER2-negative breast cancer! 🎉 The 13th #ADC approval offering new hope for patients.

Thanks to AstraZeneca & Daiichi Sankyo for this major milestone!
https://t.co/s725Sb99sh

#FDAApproval #BreastCancer